ImmunityBio has reported complete responses in patients with Non-Hodgkin Waldenstrom Macroglobulinemia (WM) using a chemotherapy-free, first-in-class CD19 CAR-NK immunotherapy. This treatment, part of the BIOSHIELD platform, demonstrated tumor-agnostic potential by targeting the immune system rather than relying on chemotherapy. One patient with WM, whose bone marrow was 90% infiltrated and had failed all other therapies, achieved a complete response after a single cycle of the NK cell therapy. The lymphoma trial is currently open for enrollment. Additionally, a novel CD40 agonist antibody, 2141-V11, showed tumor remission in aggressive cancers during a Phase I trial, with minimal toxicity and systemic immune responses observed. Real-world data also highlighted the feasibility of CAR T-cell therapy in patients with aggressive lymphomas and active autoimmune disease. Further research into immunotherapy continues, including studies on tumor cell macropinocytosis inhibition to overcome anti-PD1 resistance and a forthcoming webinar on proteomics-driven approaches to study T-cell exhaustion for identifying immunotherapy targets.